港股異動 | 中國同輻(1763.HK)漲4.41% 合肥原子高通醫藥正式運營
格隆匯8月18日丨中國同輻(1763.HK)漲4.41% ,報31.95港元,本月累計漲幅近60%,總市值102億港元。

公司附屬原子高科股份有限公司控股子公司——合肥原子高通醫藥有限公司於6月29日順利通過GMP符合性檢查,取得鍀即時標記藥品正式投產運營的合規性許可,並於8月12日正式投入運營。合肥原子高通的投產運營,進一步完善了原子高科全國醫藥中心的網絡佈局。
此外,8月13日,公司與核工業總醫院簽訂戰略合作框架協議。此次雙方合力打通核技術應用中的核特色醫療前端和應用產業鏈,為公司核技術應用人才培養、科技創新、產業發展提供了重要支撐。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.